JOHNSON & JOHNSON | Access to COVID-19 Products at JNJ

Status
31.78% votes in favour
AGM date
Previous AGM date
Proposal number
4
Resolution details
Company ticker
JNJ
Lead filer
Oxfam
Co-filers
Mercy Investment Services, Inc.
Resolution ask
Report on or disclose
ESG theme
  • Social
ESG sub-theme
  • Public health
Type of vote
Shareholder proposal
Filer type
Shareholder
Company sector
Health Care
Company HQ country
United States
Resolved clause
RESOLVED that shareholders of Johnson & Johnson ("JNJ") ask the Board of Directors to report to shareholders, at reasonable expense and omitting confidential and proprietary information, on whether and how JNJ subsidiary Janssen's receipt of government financial support for development and manufacture of vaccines and therapeutics for COVID-19 is being, or will be, taken into account when engaging in conduct that affects access to such products, such as setting prices.
Supporting statement
Janssen has received substantial government funding for research and development related to COVID-19. In February 2020, Janssen entered into a "collaborative partnership" pursuant to which the U.S. Biomedical Advanced Research and Development Authority ("BARDA") provided $456 million to develop a vaccine candidate for COVID-19,1 and BARDA agreed to pay $152 million for Janssen and a partner to screen compounds for efficacy in treating COVID-19.2 BARDA committed $1 billion to Janssen in August to fund expansion of vaccine manufacturing capability; the agreement entitles the federal government to 100 million doses.3

JNJ stated publicly that it will distribute a COVID-19 vaccine on a "nonprofit" basis, but that commitment is limited to "emergency pandemic use."4 JNJ has not clarified what "nonprofit" means when the government funds a significant portion of the research and development cost. If a COVID-19 vaccine must be readministered regularly to maintain herd immunity, as many experts predict,5 demand will outlast the pandemic, and the potential market will be vast.

If JNJ's vaccine is approved, scaling up production beyond JNJ's goal of producing 1 billion doses per year6 will be essential to ensure universal and low-cost vaccine access, which is critical to maintain stability, reignite the global economy and investor returns,7 and prevent domestic outbreaks.8 Accordingly, JNJ will face enormous pressure to share intellectual property (including patents) over the COVID-19 vaccines or therapeutics to which public entities such as BARDA are contributing. Already, Janssen's agreements with BARDA have been criticized for limiting the government's intellectual property rights,9 which could place a chokehold on mass production commensurate with global need-increasing price, decreasing overall supply and preventing universal access.

JNJ's 2019 Transparency Report-pre-dating COVID-19-describes the factors it considers in pricing: balancing the value of a medicine, the "importance of preserving [JNJ's] ability to develop future groundbreaking cures and treatments," and ensuring affordable access.10 Yet, JNJ does not at present disclose how public financial support factors into its approach to ensuring access over its COVID-19 products. This Proposal seeks to overcome this gap by asking JNJ to explain whether and how the significant contribution from public entities to the COVID-19 products JNJ seeks to commercialize affects, or will affect, its analysis of those factors and of actions, including pricing, that it could take to ensure access.

How other organisations have declared their voting intentions

Organisation name Declared voting intentions Rationale
Aktia Bank p.l.c. For The requested disclosure around public funding consideration could benefit shareholders in assessing the company's oversight of associated risks.

DISCLAIMER: By including a shareholder resolution or management proposal in this database, neither the PRI nor the sponsor of the resolution or proposal is seeking authority to act as proxy for any shareholder; shareholders should vote their proxies in accordance with their own policies and requirements.

Any voting recommendations set forth in the descriptions of the resolutions and management proposals included in this database are made by the sponsors of those resolutions and proposals, and do not represent the views of the PRI.

Information on the shareholder resolutions, management proposals and votes in this database have been obtained from sources that are believed to be reliable, but the PRI does not represent that it is accurate, complete, or up-to-date, including information relating to resolutions and management proposals, other signatories’ vote pre-declarations (including voting rationales), or the current status of a resolution or proposal. You should consult companies’ proxy statements for complete information on all matters to be voted on at a meeting.